All Pharma News
price-trendAsk Us
Pfizer snaps up rights to RSV therapy left behind in ReViral

Pfizer snaps up rights to RSV therapy left behind in ReViral
Gabrielle Masson FIERCEBIOTECH
20 Dec 2022
Share Share
Pfizer Completes Acquisition Of ReViral

Pfizer Completes Acquisition Of ReViral
CPI
10 Jun 2022
Share Share
Pfizer buys a private biotech and its RSV drug research

Pfizer buys a private biotech and its RSV drug research
K. Jensen BIOPHARMADIVE
08 Apr 2022
Share Share
ReViral Appoints Brett Haumann as Chief Medical Officer

ReViral Appoints Brett Haumann as Chief Medical Officer
BUSINESSWIRE
17 Jan 2022
Share Share
ReViral to continue Phase II paediatric trial of sisunatovir for RSV

ReViral to continue Phase II paediatric trial of sisunatovir for RSV
CLINICAL TRAILS ARENA
17 Jun 2021
Share Share
ReViral Announces Positive Recommendation by the DSMC for Sisunatovir

ReViral Announces Positive Recommendation by the DSMC for Sisunatovir
BUSINESSWIRE
16 Jun 2021
Share Share
ReViral and LianBio Announce Exclusive Collaboration and License Agreement

ReViral and LianBio Announce Exclusive Collaboration and License Agreement
BUSINESSWIRE
02 Mar 2021
Share Share
ReViral Raises $44 Million in Series C Financing

ReViral Raises $44 Million in Series C Financing
BUSINESSWIRE
25 Aug 2020
Share Share